Announced Tue, 18 Aug · 08:40 IST
Biocon gets U.S. FDA nod for Yesintek autoinjector format
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.2%1-day move
₹412.00
prior close
₹413.50
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4-0.2+0.0+0.5+0.2+0.1+0.9———————
Up moveDown movePending
AI summary
Biocon's U.S. subsidiary received supplemental U.S. FDA approval for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjector in 45 mg/0.5 ml and 90 mg/ml strengths. The drug treats moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. Yesintek was originally approved in November 2024. This new delivery format strengthens Biocon's U.S. immunology portfolio.
Likely market impact
New patient-friendly delivery format expands Biocon's U.S. immunology portfolio, which could support revenue growth.